AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE’S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE AB Science SA (Euronext - FR0010557264 - AB) announces that ...
AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd’s Syndicate 1902, for its Phase III clinical trial ...
AB Science (ABSCF) is running a late-stage study of masitinib in progressive multiple sclerosis, a severe form of the disease with limited options. The trial, officially titled “A 96-Week, Prospective ...
AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...
Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, ...
While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
PRESS RELEASE FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0 ...
French biotech company AB Science has been studying its lead compound, masitinib, for a dozen years, but so far it has only won approval to market the compound to treat dogs with cancer in the U.S.
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory ...
THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results